Clinical Efficacy and Safety Analysis of Lurasidone in the Treatment of Schizophrenia
Objective:To investigate the clinical effect and safety of Lurasidone in the treatment of schizophrenia.Method:A total of 200 patients with schizophrenia who were hospitalized in the Third People's Hospital of Ganzhou from January 1st to December 31st,2022 were selected as the study subjects and divided into study group(n=100)and control group(n=100)according to random number table method.The control group was treated with Ziprasidone,and the study group was treated with Lurasidone.The clinical efficacy,safety,neuro-related factors and cognitive function of the two groups were compared.Result:After treatment,the scores of repeatable battery for the assessment of neuropsychological status(RBANS)and the levels of neuron specific enolase(NSE),nerve growth factor(NGF)and S100 calcium-binding protein B(S100B)in both groups were improved compared with those before treatment,and the levels of NSE and S100B in the study group were lower than those in the control group,each item scores and total scores of RBANS and NGF level were higher than those of control group(P<0.05).The total effective rate of the study group(96.00%)was higher than that of the control group(82.00%)(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Lurasidone has a significant effect in the treatment of schizophrenia,which can effectively improve patients'cognitive function and nerve-related factors,and has high safety.
万方数据
维普
